Ascentage Pharma Group International ADR Dossier
Qualitative Analysis
Business overview
Ascentage Pharma Group International is a global, commercial-stage, integrated biopharmaceutical company dedicated to discovering, developing, and commercializing novel, differentiated therapies for cancer, hepatitis B virus (HBV), and age-related diseases. The company is a pioneer in targeting protein-protein interactions to restore apoptotic pathways, with a robust pipeline of inhibitors targeting Bcl-2, MDM2-p53, and IAP, alongside next-generation kinase inhibitors. Its first approved product, Olverembatinib (HQP1351), is a third-generation BCR-ABL1 inhibitor approved in China for patients with chronic myeloid leukemia (CML). Its second commercial asset, Lisaftoclax (APG-2575), is a selective Bcl-2 inhibitor launched in China in late July 2025. Ascentage is listed on both the Hong Kong Stock Exchange (6855.HK) and the Nasdaq Global Market (AAPG).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing nine global registrational Phase III clinical trials, including four cleared by the FDA and EMA, to establish global leadership in hematology-oncology.
Expected impact: Securing global regulatory approvals for core assets Olverembatinib and Lisaftoclax.
Expanding the in-house commercial team to over 270 members and establishing strategic partnerships with leading pharmaceutical distributors in China.
Expected impact: Achieving nationwide drug distribution coverage and maximizing market penetration for newly launched therapies.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Takeda an exclusive option to license global rights to develop and commercialize Olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan, and Russia.
Terms: Ascentage received a US$100 million upfront option payment in July 2024, and is eligible for an option exercise fee, additional potential milestone payments of up to approximately US$1.2 billion, and double-digit royalties on annual sales.
Jointly conducting a registrational Phase III study of Lisaftoclax in combination with AstraZeneca's Calquence (acalabrutinib) in treatment-naive patients with first-line CLL/SLL.
Terms: Collaborative clinical development terms.
Joint clinical development and commercialization of Olverembatinib in China, and collaborative clinical development of Lisaftoclax in combination with Innovent's rituximab biosimilar and anti-CD47 monoclonal antibody.
Terms: Includes equity subscription of US$50 million by Innovent and stock warrants.